Evidence map›Paper›PMID 16054715›Full record

ReviewInternational journal of cardiology2006

Effects of statins beyond lipid lowering: potential for clinical benefits.

Khalid Almuti, Rola Rimawi, Daniel Spevack, Robert J Ostfeld

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in International journal of cardiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03007524 (A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome), which is not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03007524 phase4unknown statusstarted 2016, after this paper: background citation

A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome

Ran2016Enrolled80Registered outcomes25Posted comparisons0ConditionsAcute Coronary SyndromeArmsHigh dose Rosuvastatin, Low dose Rosuvastatin
Open the trial in the graph
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Khalid AlmutiDepartment of Medicine, Montefiore Medical Center, Bronx, New York, USA.
Rola Rimawi
Daniel Spevack
Robert J Ostfeld

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe role of statin drugs in the reduction of serum lipids has been well documented. More recently, evidence suggesting that statins may positively impact many organ systems and disease states independent of lipid reduction has emerged. The term "pleiotropic effects" has been used to refer to these properties. We reviewed the evidence exploring such potential effects.

methodsA search of the MEDLINE database was conducted for articles published between 1985 to 2005 on the pleiotropic and the lipid-lowering independent effects of statin drugs. The search terms "statin", "HMG-CoA reductase inhibitor", "pleiotropic effects", and "inflammation" were used. English language articles were selected for inclusion along with selected cross-references.

resultsNumerous animal and clinical studies support the presence of a spectrum of beneficial effects for statins that are independent of their lipid-lowering properties. These effects are mediated by a variety of mechanisms and they suggest that the therapeutic role of statins may expand.

conclusionStatins have shown great promise beyond their lipid-lowering effects. Ongoing and future studies will help to further clarify the potential clinical impact of these "pleiotropic effects".

Indexed as

AnimalsAnti-Inflammatory AgentsAutoimmune DiseasesCell ProliferationCentral Nervous System DiseasesCholesterol, LDLCoronary Artery DiseaseDiabetic NephropathiesEndothelium, VascularGastrointestinal DiseasesHeart FailureHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMuscle, Smooth, VascularSepsisThrombosisAnti-Inflammatory AgentsCholesterol, LDLHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.